BioMedInnovations CEO Carrie DiMarzio presented at the WFIRM Regenerative Medicine Essentials Course and World Stem Cell Summit held co-jointly and virtually on June 8th, 2022, during the “REG MED NEXUS FOR ECONOMIC DEVELOPMENT
The Regenerative Medicine Essential Course provides a state-of-the-art review of various aspects of regenerative medicine, addressing fundamental principles and recent progress in tissue engineering and regenerative medicine. The Virtual World Stem Cell Summit is a global, trans-disciplinary, super-ecosystem event designed to break down barriers, expand knowledge, and forge collaborations with the collective goal of improving healthcare and delivering cures.
Carrie spoke on BMI’s patented cardio-vascular emulating CaVESWave® system as a versatile ex vivo and pharmacodynamic research platform and then discussed bringing related multi-organ OrganBank products to the market (OrganBankTM, OrganBankTM Transport Unit, DEVOL Solution Perfusate, and related products).
This talk included pre-clinical trial data regarding normothermic kidney preservation for greater than 24 hours using BMI technology and the application of BMI technology to enable advances in regenerative medicine and accelerate research in drug development and gene therapy. Examples included applying the perfusion technology to study complex colloidal artificial oxygen nano-carriers adapted to machine perfusion. Carrie also highlighted the proprietary advantages of OrganBank products, which include temperature-controlled perfusion, extended preservation times, auto-adjusted perfusion flow, the ability to recover organs, the application of all organs to a single platform, and real-time tracking and vital metrics.
Finally, Carrie discussed the benefits of being in the RegeneratOR Innovation Accelerator from the RegenMed Development Organization (ReMDO), which supports innovation from research to commercialization for regenerative medicine start-ups and growth companies by providing space and support, including market potential validation, benefits analysis, financial planning, budgeting, and comprehensive business plans. The overall goal of the RegeneratOR Innovation Accelerator is to move new medical capabilities and treatments closer to the market and patients in need.
*BMI intends to seek FDA Clearance for its first mobile device in 2023 and once secured to begin by focusing on the Kidney Transplant market.”
